EA201201007A1 - Твердая фармацевтическая композиция для буккального введения агомелатина - Google Patents

Твердая фармацевтическая композиция для буккального введения агомелатина

Info

Publication number
EA201201007A1
EA201201007A1 EA201201007A EA201201007A EA201201007A1 EA 201201007 A1 EA201201007 A1 EA 201201007A1 EA 201201007 A EA201201007 A EA 201201007A EA 201201007 A EA201201007 A EA 201201007A EA 201201007 A1 EA201201007 A1 EA 201201007A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
agomelatin
buckle
introduction
solid pharmaceutical
Prior art date
Application number
EA201201007A
Other languages
English (en)
Inventor
Франсуа Тарро
Сесиль Пуарье
Жилль Фонкнехтен
Жан-Манюэль Пеан
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46603817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201007(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA201201007A1 publication Critical patent/EA201201007A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к твердой буккальной фармацевтической композиции, содержащей агомелатин, предназначенный для системного действия.
EA201201007A 2011-08-10 2012-08-09 Твердая фармацевтическая композиция для буккального введения агомелатина EA201201007A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1102500A FR2978916B1 (fr) 2011-08-10 2011-08-10 Composition pharmaceutique solide pour administration buccale d'agomelatine

Publications (1)

Publication Number Publication Date
EA201201007A1 true EA201201007A1 (ru) 2013-03-29

Family

ID=46603817

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201007A EA201201007A1 (ru) 2011-08-10 2012-08-09 Твердая фармацевтическая композиция для буккального введения агомелатина

Country Status (28)

Country Link
US (1) US20130041040A1 (ru)
EP (1) EP2556824A1 (ru)
JP (1) JP2013040170A (ru)
KR (1) KR20130018156A (ru)
CN (1) CN102949360A (ru)
AP (1) AP2012006411A0 (ru)
AR (1) AR087490A1 (ru)
AU (1) AU2012211406A1 (ru)
BR (1) BR102012020320A2 (ru)
CA (1) CA2784853A1 (ru)
CL (1) CL2012002203A1 (ru)
CO (1) CO6620024A1 (ru)
CR (1) CR20120409A (ru)
CU (1) CU20120115A7 (ru)
EA (1) EA201201007A1 (ru)
EC (1) ECSP12012088A (ru)
FR (1) FR2978916B1 (ru)
GT (1) GT201200237A (ru)
MD (1) MD20120062A3 (ru)
MX (1) MX2012009148A (ru)
NI (1) NI201200130A (ru)
PE (1) PE20130381A1 (ru)
RU (1) RU2014108915A (ru)
SG (1) SG188042A1 (ru)
TW (1) TW201311233A (ru)
UY (1) UY34238A (ru)
WO (1) WO2013021139A1 (ru)
ZA (1) ZA201205978B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028335A (zh) * 2021-12-24 2022-02-11 山东京卫制药有限公司 一种阿戈美拉汀溶液鼻喷剂及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
JP2642354B2 (ja) * 1987-06-11 1997-08-20 株式会社 三和化学研究所 徐放性バッカル剤の製法
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
ES2206709T3 (es) * 1996-05-13 2004-05-16 Novartis Consumer Health S.A. Sistema de suministro bucal.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
FR2823974B1 (fr) * 2001-04-25 2004-10-15 Pf Medicament Pastille medicamenteuse a liberation lente du principe actif
PL208787B1 (pl) 2001-09-19 2011-06-30 Merck Patent Gmbh (2R, 4R/S)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol i (2R, 4R)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol, sposoby ich otrzymywania i zastosowanie do wytwarzania preparatów medycznych oraz zawierająca je kompozycja farmaceutyczna
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US7579442B2 (en) * 2002-04-16 2009-08-25 Ocugenics, LLC Method for stromal corneal repair and refractive alteration
JP4251907B2 (ja) 2003-04-17 2009-04-08 シャープ株式会社 画像データ作成装置
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
KR20060122027A (ko) 2005-05-25 2006-11-30 엘지전자 주식회사 콘텐츠용 이동통신 단말기
FR2889522B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
CN100376765C (zh) 2005-10-28 2008-03-26 中国科学院工程热物理研究所 一种用于多级叶轮机的三维时序效益最大化方法
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
JP2009538331A (ja) * 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
WO2007137224A2 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
EP2195462B1 (en) * 2007-09-13 2013-06-12 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009137531A2 (en) * 2008-05-06 2009-11-12 Somaxon Pharmaceuticals, Inc. Compositions and methods related to action of low dosages of doxepin on the h1 and 5-ht2a receptors
CN101481321B (zh) 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN101991577A (zh) * 2009-08-19 2011-03-30 北京利乐生制药科技有限公司 新型精神类药物组合物
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
CN102050756A (zh) 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102190594A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN102190595A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN101870662B (zh) 2010-05-21 2013-03-20 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
WO2012046253A2 (en) 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CN102030673B (zh) 2010-11-24 2014-04-23 威海迪素制药有限公司 一种阿戈美拉汀新晶型及制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
CN102206864B (zh) 2011-04-13 2012-10-03 吉林省博大伟业制药有限公司 阿戈美拉汀的ⅵ晶型单晶及混合晶型和制备方法
CN102503886B (zh) 2011-10-11 2013-09-11 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN102432490A (zh) 2011-11-02 2012-05-02 江西施美制药有限公司 一种阿戈美拉汀晶型d及其制备方法

Also Published As

Publication number Publication date
ZA201205978B (en) 2013-05-29
KR20130018156A (ko) 2013-02-20
EP2556824A1 (fr) 2013-02-13
MD20120062A3 (ru) 2016-06-30
CA2784853A1 (fr) 2013-02-10
ECSP12012088A (es) 2014-03-31
MD20120062A2 (en) 2013-02-28
WO2013021139A1 (fr) 2013-02-14
PE20130381A1 (es) 2013-04-06
MX2012009148A (es) 2013-02-21
NI201200130A (es) 2013-02-05
AR087490A1 (es) 2014-03-26
FR2978916B1 (fr) 2013-07-26
US20130041040A1 (en) 2013-02-14
CU20120115A7 (es) 2012-10-15
JP2013040170A (ja) 2013-02-28
BR102012020320A2 (pt) 2013-10-29
CO6620024A1 (es) 2013-02-15
RU2014108915A (ru) 2015-09-20
CR20120409A (es) 2013-05-16
AU2012211406A1 (en) 2013-02-28
SG188042A1 (en) 2013-03-28
AP2012006411A0 (en) 2012-08-31
NZ601713A (en) 2014-01-31
GT201200237A (es) 2014-08-11
TW201311233A (zh) 2013-03-16
FR2978916A1 (fr) 2013-02-15
CL2012002203A1 (es) 2012-11-23
CN102949360A (zh) 2013-03-06
UY34238A (es) 2013-02-28

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
BR112013030885A2 (pt) composição de stevia.
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
IL227626A0 (en) A compound of 17-il and γ-ifn inhibitors, preparations containing them and their uses
FR21C1016I1 (fr) Colonoscopie, préparation
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
TN2014000136A1 (en) Selective androgen receptor modulators
MX2014002625A (es) Nuevas composiciones para la produccion de poliamidas coladas.
BR112013019518A2 (pt) composições para cuidado oral.
BR112013030897A2 (pt) composição.
CY1126099T1 (el) Φαρμακευτικη συνθεση που περιεχει κρυσταλλικη τοσυλικη σοραφενιμπη
BR112013031544A2 (pt) composição tópica.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
BR112014032501A2 (pt) composto, e, composição farmacêutica.
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
EP2710024A4 (en) OSW-1 CONJUGATES AND ANALOGUES, AND USES THEREOF
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
IN2012DE00826A (ru)
EA201201007A1 (ru) Твердая фармацевтическая композиция для буккального введения агомелатина
IT1403537B1 (it) Composizione deodorante.
ZA201308414B (en) Solid pharmaceutical composition
EP2727594A4 (en) NEW PHARMACEUTICAL COMPOSITION
TR201104864A2 (tr) Deksketoprofen içeren suda çözünebilir formülasyonlar.
ES2396651B2 (es) Material biosanitario antiulcera.
MY151659A (en) Photopolymerizable Resin Composition